Built with thought-leaders at Sage Therapeutics, Janssen and Lundbeck the 2^nd Annual Neuropsychiatric Drug Development Summit (NPD) will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs. Uniting 90+ drug developers from all corners of the world, NPD will be your opportunity to discuss, in depth, the challenges with preclinical models, precision medicine and target selection that have been stifling the progress of your neuropsychiatric drug development.